BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34811701)

  • 1. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
    Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
    Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report.
    Gyoda Y; Ichida H; Kawano F; Takeda Y; Yoshioka R; Imamura H; Mise Y; Fukumura Y; Saiura A
    Clin J Gastroenterol; 2024 Apr; 17(2):311-318. PubMed ID: 38277091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.
    Ohya Y; Hayashida S; Tsuji A; Kuramoto K; Shibata H; Setoyama H; Hayashi H; Kuriwaki K; Sasaki M; Iizaka M; Nakahara O; Inomata Y
    Surg Case Rep; 2020 Dec; 6(1):318. PubMed ID: 33301055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.
    Hoshino T; Naganuma A; Furusawa A; Suzuki Y; Hirai K; Sakamoto I; Ogawa T; Ogawa A; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Aug; 15(4):776-783. PubMed ID: 35585285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery].
    Utsunomiya T; Sakamoto K; Iwata M; Ito C; Sakamoto A; Matsui T; Shine M; Nishi Y; Uraoka M; Nagaoka T; Tamura K; Funamizu N; Ogawa K; Kitazawa R; Takada Y
    Gan To Kagaku Ryoho; 2022 Dec; 49(12):1365-1367. PubMed ID: 36539251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
    Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
    Hidaka M; Hara T; Soyama A; Sasaki R; Matsushima H; Tanaka T; Hamada T; Imamura H; Adachi T; Kanetaka K; Miyaaki H; Okano S; Eguchi S
    Anticancer Res; 2022 Jun; 42(6):3049-3054. PubMed ID: 35641262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of advanced hepatocellular carcinoma wherein readministration was made possible due to successful transcatheter arterial embolization for intratumoral hemorrhage during Lenvatinib administration].
    Hara H; Nakano Y; Arai K; Kaneko Y; Sakaki K; Fukami Y; Ikemiyagi H; Yoshino K; Sakita S
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(5):476-485. PubMed ID: 35545547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of Vp4 hepatocellular carcinoma with tumor thrombosis extending into the confluence of the splenic/portal vein achieved a good prognosis with emergent hepatectomy and postoperative adjuvant therapy with lenvatinib.
    Kato H; Asano Y; Ito M; Arakawa S; Shimura M; Koike D; Ochi T; Yasuoka H; Kawai T; Higashiguchi T; Tani H; Kunimura Y; Kondo Y; Nagata H; Sato H; Horiguchi A
    World J Surg Oncol; 2022 Sep; 20(1):278. PubMed ID: 36057621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic Left Hepatectomy for Ruptured Hepatocellular Carcinoma Controlled After Transcatheter Arterial Embolization: Case Report and Review of the Literature.
    Yoshiya S; Iwaki K; Sakai A; Fujita S; Kawasaki T; Yoshizumi F; Hiroshige S; Okamoto M; Fukuzawa K; Motohiro A; Maehara Y
    In Vivo; 2018; 32(3):659-662. PubMed ID: 29695575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
    Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
    Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surgical Resection and Adjuvant Chemotherapy for Early Multiple Peritoneal Recurrence after Rejection of Hepatocellular Carcinoma-A Case Report].
    Yamaguchi S; Onoe T; Fujii T; Shibata Y; Tazuma S; Akimoto S; Sada H; Shimada N; Tazawa H; Suzuki T; Sudo T; Shimizu Y; Tashiro H
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1450-1452. PubMed ID: 38303304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case Involving the Re-Application of TAE for the Rupture of Recurrent Dissemination Lesion after Initial TAE and Hepatectomy Was Performed for A Previous Rupture of HCC].
    Ueda S; Hasegawa H; Kitagawa D; Shibahara K; Kitamura M
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1919-1921. PubMed ID: 29394820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
    Mukai Y; Wada H; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Kawamoto K; Marubashi S; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1638-40. PubMed ID: 26805122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case report: disappearance of cancer cells confirmed by surgical resection after transcatheter hepatic artery embolization (TAE) for ruptured hepatocellular carcinoma].
    Wakahara M; Tanaka S; Tanemura H; Ooshita H; Kanno A; Hiraoka T; Suhara T; Nakata T; Yamamoto M; Saitou S
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1903-6. PubMed ID: 10560422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
    Shindoh J; Kawamura Y; Kobayashi Y; Kobayashi M; Akuta N; Okubo S; Suzuki Y; Hashimoto M
    Ann Surg Oncol; 2021 Nov; 28(12):7663-7672. PubMed ID: 33904001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization.
    Jin YJ; Lee JW; Park SW; Lee JI; Lee DH; Kim YS; Cho SG; Jeon YS; Lee KY; Ahn SI
    World J Gastroenterol; 2013 Jul; 19(28):4537-44. PubMed ID: 23901230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.